hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06344949, orgStudyIdInfo id: B2024-074, briefTitle: Ciprofol Versus Propofol for Tracheal Intubation in ICU, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, descriptionModule briefSummary: The physiological reserves of critically ill patients are relatively low, and the risk of complications related to tracheal intubation in the ICU is higher than in the operating room. ICU tracheal intubation complications account for approximately 40% -45% of patients, including severe hypotension (10% -43%), severe hypoxemia (9% -25%), and cardiac arrest (2% -3%).Ciprofol is a novel 2,6-disubstituted phenol derivative that targeting γ-aminobutyric acid type A (GABAA)-receptor. There are four indications of ciprofol that have been approved by NMPA in recent two years: sedation and anesthesia in non-tracheal intubation procedure/operation, induction and maintenance of general anesthesia, sedation during intensive care, sedation and maintenance in gynecological outpatient surgery. The aim of this study is to compare the effects of propofol and propofol on the circulatory system during tracheal intubation in ICU patients, in order to provide a safer induction sedation regimen for emergency tracheal intubation in critically ill patients., conditionsModule conditions: Emergency Tracheal Intubation in Critically Ill Patients, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Ciprofol, interventions name: Propofol, outcomesModule primaryOutcomes measure: cardiovascular collapse within 30minutes from the start of the intubation procedure, secondaryOutcomes measure: Success rate of sedation, secondaryOutcomes measure: Successful intubation on the first attempt, secondaryOutcomes measure: Time from initiation of study drug administration to successful tracheal intubation (within 30 minutes), secondaryOutcomes measure: The incidence of cardiac arrest within 30 minutes after tracheal intubation, secondaryOutcomes measure: The incidence of bradycardia within 30 minutes after tracheal intubation, secondaryOutcomes measure: The incidence of hypoxemia within 30 minutes after tracheal intubation, secondaryOutcomes measure: new requirement or increase of vasopressors, secondaryOutcomes measure: new requirement or increase of antiarrhythmic drugs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06344936, orgStudyIdInfo id: HRS-1780-103, briefTitle: Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Shandong Suncadia Medicine Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects, conditionsModule conditions: Chronic Kidney Disease(CKD), designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules, outcomesModule primaryOutcomes measure: Assess the Cmax of HRS-1780 in plasma., primaryOutcomes measure: Assess the Tmax of HRS-1780 in plasma., primaryOutcomes measure: Assess the t1/2 of HRS-1780 in plasma., primaryOutcomes measure: Assess the AUC0-t of HRS-1780 in plasma., primaryOutcomes measure: Assess the AUC0-inf of HRS-1780 in plasma., secondaryOutcomes measure: Assess the incidence and severity of adverse events in healthy subjects after administration of HRS-1780 tablets., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Beijing Hospital, city: Beijing, state: Beijing, zip: 100730, country: China, contacts name: Xin Wang, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06344923, orgStudyIdInfo id: KYLL, briefTitle: Peritoneum and Anterior Rectus Sheath Suturing and Ileostomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Qilu Hospital of Shandong University, class: OTHER, descriptionModule briefSummary: In the era of laparoscopy, ileostomy via specimen extraction site has been proposed as a novel approach for temporary ostomy creation to prevent anastomotic leak after laparoscopic low anterior rectal resection. Whether suturing the layer of the peritoneum and anterior rectus sheath affects the safety of this novel approach has not been investigated., conditionsModule conditions: Ileostomy - Stoma, conditions: Rectal Neoplasms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing, interventions name: Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing, outcomesModule primaryOutcomes measure: postoperative complications related to ileostomy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06344910, orgStudyIdInfo id: 20230416-C1_v2, briefTitle: PRagmatic Study Of Messaging to Providers of Patients With Heart Failure in Amsterdam UMC, acronym: PROMPT-HF-AUMC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), class: OTHER, collaborators name: AstraZeneca, collaborators name: Yale University, descriptionModule briefSummary: This is a prospective cohort study, where we aim to investigate the effect of implementation of an electronic nudge alerting clinicians to the prescription of the 4 key pharmacological classes for the treatment of patients with heart failure and reduced ejection fraction (HFrEF) at the outpatient clinic in the Netherlands., conditionsModule conditions: Heart Failure With Reduced Ejection Fraction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 900, type: ESTIMATED, armsInterventionsModule interventions name: Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies, outcomesModule primaryOutcomes measure: Use of guideline-directed medical therapy (GDMT), secondaryOutcomes measure: All-cause mortality, secondaryOutcomes measure: Hospitalisation for Heart Failure, secondaryOutcomes measure: other major cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), secondaryOutcomes measure: renal events (>30% serum creatinine increase, hospitalization for acute kidney injury, development of end-stage kidney disease), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06344897, orgStudyIdInfo id: mac1, briefTitle: The Effect of Kinesio Taping in Pediatric Surgery, statusModule overallStatus: COMPLETED, startDateStruct date: 2024-02-25, primaryCompletionDateStruct date: 2024-03-21, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: KTO Karatay University, class: OTHER, collaborators name: Nigde Omer Halisdemir University, collaborators name: University of Health Sciences Konya Health Application and Research Center, descriptionModule briefSummary: This study was planned to determine the effect of kinesio taping (KT) applied to the abdominal area after surgery on pain and gas output in children aged 6-12 years who had open appendicitis surgery., conditionsModule conditions: Appendicitis, conditions: Surgery, conditions: Pain, Acute, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: The effect of kinesio taping on pain in children aged 6-12 years who had open appendicitis surgery., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: The research is in a parallel group, single-blind randomized controlled experimental design.Simple randomization will be applied to children who have had open appendicitis surgery and meet the inclusion criteria, without any stratification in the study.In order to determine which group the 68 children who meet the sample selection criteria in the study group will be included in, numbers from 1 to 68 will be randomly distributed to 2 groups through a computer program (https://www.randomizer.org/) without number repetition. 34 patients will be assigned to the experimental group and 34 patients to the control group. Since the person who will actively apply the taping in the study is the researcher, only the children will be blinded, therefore a single blind design will be applied., whoMasked: PARTICIPANT, enrollmentInfo count: 68, type: ACTUAL, armsInterventionsModule interventions name: Kinesio taping, outcomesModule primaryOutcomes measure: Kinesio tape applying affects pain in children aged 6-12 years who have appendicitis surgery., primaryOutcomes measure: Kinesio tape applying affects fear in children aged 6-12 years who have appendicitis surgery., secondaryOutcomes measure: Kinesio taping affects gas output time in children aged 6-12 years who have appendicitis surgery, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: University of Health Sciences Konya Health Application and Research Center, city: Konya, state: Karatay, zip: 42020, country: Turkey, geoPoint lat: 37.87135, lon: 32.48464, hasResults: False
protocolSection identificationModule nctId: NCT06344884, orgStudyIdInfo id: 23-2619, briefTitle: Early Patient Removal of Urinary Catheters After Urogynecologic Surgery, acronym: CARES2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: University of North Carolina, Chapel Hill, class: OTHER, descriptionModule briefSummary: Management of postoperative urinary retention often requires the use of indwelling catheters. In a previous study, the investigators determined that patient removal of catheters at home is non-inferior to standard office removal on postoperative day three or four (POD3-4). The purpose of this study is to determine whether patient removal of catheters at home on postoperative day one (POD1) is noninferior to removal on POD 3-4., conditionsModule conditions: Urinary Retention Postoperative, conditions: Postoperative Urinary Tract Infection, conditions: Catheter Site Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 128, type: ESTIMATED, armsInterventionsModule interventions name: Early catheter removal, outcomesModule primaryOutcomes measure: Number of patients with ongoing urinary retention (noninferiority), secondaryOutcomes measure: Number of patient contacts for voiding dysfunction by Type, secondaryOutcomes measure: Total patient contacts for voiding dysfunction Combined, secondaryOutcomes measure: Number of patients treated for postoperative UTI., secondaryOutcomes measure: Number of patients with ongoing urinary retention, secondaryOutcomes measure: Patient Satisfaction Survey Score-Pain, secondaryOutcomes measure: Patient Satisfaction Survey Score-Ease of Use, secondaryOutcomes measure: Patient Satisfaction Survey Score-Satisfaction, secondaryOutcomes measure: Patient Satisfaction Survey Score-Likelihood to Use Again, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UNC Health Rex, city: Raleigh, state: North Carolina, zip: 27607, country: United States, contacts name: Lauren Tholemeier, MD, role: CONTACT, phone: 984-974-0496, email: lauren_tholemeier@med.unc.edu, geoPoint lat: 35.7721, lon: -78.63861, hasResults: False
protocolSection identificationModule nctId: NCT06344871, orgStudyIdInfo id: 002, briefTitle: Exploratory Study Using a New Head-only PET Scanner / ExploreNeuroLF, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Positrigo AG, class: INDUSTRY, collaborators name: University of Zurich, collaborators name: University of Leipzig, descriptionModule briefSummary: The "NeuroLF prototype" is a small aperture PET scanner. The NeuroLF prototype will be used with patients, which have just finished their regularly scheduled PET examination on a clinical whole body PET system. The radioactive tracer used for this procedure will still be active. This remaining acitivity will be used for an image acquisition with the NeuroLF prototype without the need for an additional radioactive tracer dose.The control intervention is be a brain PET scan as part of standard clinical routine. It will be done immediately before the scan on the NeuroLF prototype., conditionsModule conditions: Brain Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: NeuroLF, interventions name: Conventional PET scan, outcomesModule primaryOutcomes measure: PET Image of the Brain, secondaryOutcomes measure: Ease of Placement (Usability), secondaryOutcomes measure: Usage of accessories for patient placement (Usability), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Leipzig, status: RECRUITING, city: Leipzig, country: Germany, contacts name: Henryk Barthel, Prof.Dr., role: CONTACT, phone: +49 341 97 18082, email: Henryk.Barthel@medizin.uni-leipzig.de, contacts name: Henryk Barthel, Prof. Dr., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 51.33962, lon: 12.37129, locations facility: University Hospital Zurich, status: NOT_YET_RECRUITING, city: Zürich, country: Switzerland, contacts name: Martin Hüllner, Prof. Dr., role: CONTACT, phone: +41 44 255 25 80, email: martin.huellner@usz.ch, contacts name: Martin Hüllner, Prof. Dr., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.36667, lon: 8.54999, hasResults: False
protocolSection identificationModule nctId: NCT06344858, orgStudyIdInfo id: 124/2021, briefTitle: Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI, acronym: Keta-ANI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Pontificia Universidad Catolica de Chile, class: OTHER, descriptionModule briefSummary: Ketamine, an intravenous anesthetic, and analgesic agent has experienced a resurgence in its clinical application, particularly in subanesthetic doses. The aim of this observational study is to characterize the changes in the Nociception Analgesia Index (ANI) associated with the administration of an intravenous ketamine bolus using a Pharmacokinetic-Pharmacodynamic (PKPD) modeling approach. The pharmacokinetic parameters of the Domino model will be used to predict ketamine plasma concentrations after the bolus dose. An Emax model and a link model assuming a first order rate constant (ke0) will be used to fit the data. Modeling analysis will use the program NONMEM. It is expected to recruit a total of 20 patients between 40 and 80 years, ASA I, II or III, programmed for elective surgery with general anesthesia. ANI values will be recorded every 6 seconds for 5 minutes from the bolus dose., conditionsModule conditions: Analgesia, conditions: Ketamine, conditions: Pharmacokinetic, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Ketamine, outcomesModule primaryOutcomes measure: To measure ANI values after ketamine bolus dose administration., primaryOutcomes measure: To determine the time maximum predicted concentrations in each patient, primaryOutcomes measure: To determine the time to maximum effect of a bolus dose of ketamine, primaryOutcomes measure: To predict ketamine plasma concentrations values after ketamine bolus, primaryOutcomes measure: To calculate the difference between the time of maximum ANI effect, secondaryOutcomes measure: Patient weight, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pontificia Universidad Catolica de Chile, city: Santiago, state: Metropolitana, zip: 450881, country: Chile, geoPoint lat: -33.45694, lon: -70.64827, hasResults: False
protocolSection identificationModule nctId: NCT06344845, orgStudyIdInfo id: PUMCH-NM-PBB3, briefTitle: Clinical Study of [18F] PM-PBB3 PET Imaging of Tau Protein in Neurodegenerative Diseases, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-11-01, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2025-11, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: In terms of the diagnostic technology of brain neurodegenerative diseases, the injection of positron tracers into the human body, so that it can combine with the corresponding protein, and show its distribution through PET imaging is a mature technology in the industry. At present, several research groups around the world are working on the development and clinical efficacy evaluation of their respective tau imaging agent compounds.This clinical research project intends to display the abnormal changes of tau protein in living brain through \[18F\]PM-PBB3 PET imaging, which is a second-generation tracer further optimized on the basis of \[11C\]PBB3, and has the advantages of closer binding to tau protein entanglement and less non-specific binding than similar imaging agents. Better image quality and a wider range of clinical applications., conditionsModule conditions: Neurodegenerative Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: 18F-PBB3 PET/CT scan, outcomesModule primaryOutcomes measure: Diagnostic Performance, secondaryOutcomes measure: Clinical Stage, eligibilityModule sex: ALL, minimumAge: 49 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100730, country: China, contacts name: Chenhao Jia, M.D., role: CONTACT, phone: 18548703382, email: jiachenhao24@163.com, contacts name: Ruixue Cui, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06344832, orgStudyIdInfo id: K5098, briefTitle: SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2028-03-01, completionDateStruct date: 2030-03-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Peking Union Medical College Hospital, class: OTHER, descriptionModule briefSummary: The research aims to prospectively include patients with GEP-NENs, undergo preoperative imaging assessment (including PET/CT and contrast-enhanced CT), and accurately delineate lymph node regions. Through postoperative pathological reports, the diagnostic performance of lymph node metastasis (LNM) in GEP-NENs is evaluated. Factors influencing the diagnostic accuracy of SSTR-PET/CT and contrast-enhanced CT are also investigated., conditionsModule conditions: Gastro-entero-pancreatic Neuroendocrine Tumor, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, outcomesModule primaryOutcomes measure: lymph node metastasis status, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False